Literature DB >> 17377982

Category IV indications for therapeutic apheresis: ASFA fourth special issue.

Beth H Shaz1, Michael L Linenberger, Nicholas Bandarenko, Jeffrey L Winters, Haewon C Kim, Marisa B Marques, Ravindra Sarode, Joseph Schwartz, Robert Weinstein, Ashka Wirk, Zbigniew M Szczepiorkowski.   

Abstract

The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category I, II, III, IV, and P). The diseases, which were classified as category IV indications, and the rationale for such assignment are reviewed in this article. The diseases assigned to category I, II, III, and newly created category P are discussed in a separate article in this issue.

Mesh:

Year:  2007        PMID: 17377982     DOI: 10.1002/jca.20131

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

1.  Plasmapheresis in Pediatric Intensive Care Unit.

Authors:  Verica Misanovic; Danka Pokrajac; Smail Zubcevic; Admir Hadzimuratovic; Samra Rahmanovic; Selma Dizdar; Asmir Jonuzi; Edin Begic
Journal:  Med Arch       Date:  2016-10-25

2.  Eculizumab in chemotherapy-induced thrombotic microangiopathy.

Authors:  Lena Schulte-Kemna; Barbara Reister; Lucas Bettac; Ulla Ludwig; Daniel Fürst; Joannis Mytilineos; Carsten Bergmann; Rene van Erp; Bernd Schröppel
Journal:  Clin Nephrol Case Stud       Date:  2020-04-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.